reason report
strong symdeko launch boost top line tax effect ep
come pt
bottom line vertex report financi result
deliv solid revenu beat vs consensu
vs estim accompani earn beat
vs consensu vs estim main driver
posit perform impress launch compani
alreadi achiev signific increment adopt us
appar widespread reimburs privat public payer
importantli signific new patient adopt rather
cannib orkambi fact appear less one third
symdeko revenu come directli orkambi initi
adopt come non-treat patient either discontinu
refus orkambi symdeko primari driver vertex
revenu growth yoy amongst cf product kalydeco grew
yoy driven adopt new indic patient popul
compar sale orkambi us
kalydeco flat show effect compel
profil symdeko vertex offer littl encourag progress
secur reimburs orkambi major intern market
provid addit color achiev expect file
first tripl combin seem achiev
assum continu enrol pivot trial vertex explain
chang expens earn report includ
transit full statutori tax rate pro forma basi
although cash basi adjust forecast
chang well strong launch symdeko associ
effect orkambi kalydeco revenu forecast
increas later year larg unchang ebit
forecast increas larg unchang
later year pro forma ep estim increas
reduc
subsequ year effect full taxat lower later period
given prior expect pro forma earn would reflect full
taxat within year still see signific opportun
compani tripl combin vertex stock perform strongli
plan fulli updat cf market model near futur
assess revenu opportun vertex sever competit
disappoint stumbl cf reiter outperform
rate increas price target
average ep rev
disc dcf wacc
tg
net debt total capit
price-to-earnings lt ep growth
compani inform leerink partner llc research
revenu million ep dilut exclud option expens
pleas refer page import disclosur price chart analyst certif
price target vertex rate stock outperform thesi base
expect continu captur cystic fibrosi cf patient subpopul vertex
success iter cf modul oral combin medicin expect
vertex cf revenu line grow steadili
probabl success tripl combin valuat account
full expect valu cf portfolio consid competitor forecast
valuat believ develop path time market challeng vertex
well posit partner acquir show promis flirt profit
past vertex seem determin maintain recent recov profit appear
capabl grow oper margin end
beyond compani still aspir discov develop drug categori larg
diversifi invest associ expens risk thesi valuat
howev potenti sizabl near-term growth stock offer strong valuat upsid
potenti next month
driven symdeko revenu grew qoq yoy beat consensu
vertex total cf revenu led rapid uptak symdeko
consensu forecast gross margin line consensu
expect vertex non-gaap total oper expens
slightli higher consensu forecast increas year-over-year
spend sg due increas invest cf pipelin
notabl pivot trial tripl combin regimen expens seem like
increas throughout year
vertex increas revenu guidanc previous
reiter combin sg spend midpoint rang repres
approxim growth new rang complet recent consensu
prior forecast increas product revenu guidanc reflect continu uptak
increas demand symdeko us among cf patient age vertex
chang guidanc combin non-gaap sg expens compani
cash market secur end increas result
non-gaap ep estim consensu
symdeko alon account total cf revenu sign slow
symdeko met strong demand follow us launch februari vertex
report symdeko sale beat consensu estim
signific margin reinforc opportun present across larg cap biopharma
stock success launch symdeko demand especi strong
discontinu never start orkambi although earli day see favor trend
persist complianc symdeko symdeko approv canada june
treat patient age mutat vertex expect approv
symdeko eu
kalydeco also beat orkambi suffer eros symdeko despit oldest
vertex cf medicin kalydeco sale consensu
forecast grew yoy howev compar kalydeco saw growth
loss revenu us addit orkambi saw drop yoy total sale
miss estim consensu manag postul
loss orkambi sale even lesser growth demonstr kalydeco sale may partial
attribut patient switch symdeko treatment importantli howev total revenu
beat consensu estim show substanti increment
market penetr valu transit symdeko
clinic trial tripl combin track increment indic ahead kalydeco
orkambi vertex expect complet enrol phase tripl combin program
contain toward end compani expect submit nda
later compani also expect regulatori approv
expand popul indic kalydeco orkambi younger patient fda approv
pend kalydeco age month orkambi age august
addit data expect phase studi evalu kalydeco children
infant age symdeko age new indic like give
exist product signific rel rapid revenu boost
non-cf pipelin program come focu vertex select
inhibitor repres first proof concept inhibit treatment acut
pain chronic inflammatori pain recent gener phase data provid
import clinic valid compound vertex disclos halt
develop anoth pain treatment due pk toler issu
vertex also expect report result phase ii studi neuropath pain involv
select sodium channel blocker addit plan place begin phase i/ii
studi two indic gene edit candid partner crispr
therapeut incorpor crispr technolog initi
studi pair phase i/ii trial beta-thalassemia sickl cell diseas earlier
quarter fda place clinic hold vertex attempt address
concern program rais fda vertex partner crispr
approv clinic trial applic cta uk canada clinic trial
revenu forecast larg unchang new tax treatment nol put pressur ep
price increas base today disclosur made adjust
model lower revenu forecast orkambi given on-going trend transit
symdeko off-set higher forecast kalydeco symdeko net result higher
total revenu forecast /- revenu forecast
recent consensu significantli consensu
although forecast actual oper expens littl chang ep forecast
impact new tax treatment compani disclos convers start
januari vertex record non-cash tax expens non-gaap incom statement
rate close statutori tax rate actual cash tax paid affect net
oper loss nol exhaust end expect run mid-
result chang pro forma ep forecast higher
lower ep forecast still consensu year
except adjust
price target increas reiter outperform rate vertex stock
price target vertex base simpl averag three approach
believ reason basi valu stock today approach simpl price
earn multipl higher growth larg cap biopharmaceut compani price sale
multipl mid larg cap high growth biopharmaceut compani discount cash
flow dcf use current averag high growth larg cap biopharma multipl ep
nvo azn appli current ep estim
discount back year compani cost equiti give valu
one year use averag high growth larg cap biotech price-to-revenu multipl
sale nvo appli revenu estim
post-tripl discount back year compani cost equiti give
valu one year lastli dcf valuat given wacc termin cash
flow growth rate give present valu averag three method
current price target
risk view outlook valuat vertex includ major chang price
reimburs coverag label competit posit kalydeco orkambi
compani main product today major risk disappoint delay failur
compani develop regulatori file novel tripl combin medicin
cystic fibrosi risk includ continu lack access reimburs vertex
medicin acceler success develop altern modul cftr
altern approach treat cf gene therapi final compani histori
spend much potenti earn expens diversifi acquisit could undermin
futur expect valu compani cf portfolio opportun better-than expect
perform includ realiz signific revenu compani current cf dual
combin market outsid us well acceler clinic develop tripl
sale non-gaap
non-gaap interest expens net
share count period basic
share count period dilut
guidanc
leerink partner research compani file zack factset consensu
leerink partner research compani file zack factset consensu
time result
cf children year old
cf children age month
cf infant age month
cf age
eu approv
het min cf cf
het min cf cf
late stage pipelin program includ
late stage pipelin program exclud
million
product sale direct product sale vertex
sale
forma tax excl nol benefit cash
 total revenu
sg total revenu
tax rate note differ pro forma due nol benefit cash
leerink partner research compani file
leerink vertex select balanc sheet cash-flow item
million
total liabil sharehold equiti
chang asset liabil
chang market secur
purchas treasuri stock
chang capit stock net
net chang cash/equival
begin period
end period
 increas work capit
 acquisit licens invest
oper
leerink partner research compani file
analysi stock price leerink target
method large-cap healthcar ep multipl lp normal earn
current averag growth larg cap biopharma multipl ep nvo azn
leerink ep
impli price ep use current consensu high growth larg cap multipl
equiti
number period
impli one year target price approach
method discount futur valu normal revenu use mid larg cap biotech compar
averag growth larg cap mid cap biotech price-to-revenu multipl sale
impli vertex enterpris valu sale estimate mm
estimate net
impli vertex equiti valu mm
equiti
number period
impli vertex valu mm
impli one year target price approach
method dcf base current product po adjust outlook cf franchis use wacc
present valu late stage market product flow
net debt end
averag method
leerink partner research compani file factset
